Clinical Trial

A Study of AL58805 in Patients With Advanced Tumors

Recruiting Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated September 17, 2025 (before its estimated January 26, 2026 completion). Its status may not reflect the trial's current state.
Summary
This Phase I clinical trial is a dose-escalation, multicenter study in patients with advanced solid tumors. It includes tolerance studies of sequential multiple oral doses of AL58805 and pharmacokinetic studies of single and multiple doses, analyzing the tolerance range of multiple doses, observing the maximum tolerated dose (MTD) and dose-limiting toxicity (DLT) in solid tumor patients, and assessing the reversibility of toxicity and the relationship between toxicity and dose.
Trial Details
NCT Number NCT07179081
Lead Sponsor Advenchen Laboratories Nanjing Ltd.
Conditions Advanced Tumors
Enrollment 40 participants
Start Date 2020-12-20
Primary Completion 2026-01-26 (estimated)
Study Completion 2026-01-26 (estimated)
Updated on ClinicalTrials.gov 2025-09-17